Nektar's NKTR-214 IO Deal With Bristol Looks Even Sweeter With More Data

 
• By Emily Hayes

Stock soars yet again with a positive data update for immuno-oncology star NKTR-214, a better-than-expected fourth quarter and catalysts for other pipeline candidates coming soon.

Honey - natural honey

More from Clinical Trials

More from R&D